A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B

Sponsor
Pfizer (Industry)
Overall Status
Completed
CT.gov ID
NCT00002306
Collaborator
(none)
14

Study Details

Study Description

Brief Summary

To evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal meningitis in patients who have had an unsatisfactory response to or have experienced unacceptable toxicity with amphotericin B.

Condition or Disease Intervention/Treatment Phase
N/A

Study Design

Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Multi-Center Evaluation of Fluconazole (UK-49,858) as Treatment for Acute Cryptococcal Meningitis in Patients Who Have Failed to Respond or Have Experienced Unacceptable Toxicity During Treatment With Amphotericin B

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    13 Years to 0 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    Concurrent Medication:
    Allowed:
    • Immunosuppressant therapy.

    • Antiviral therapy such as zidovudine.

    • Prophylaxis for Pneumocystis carinii pneumonia.

    • Aerosolized pentamidine.

    Concurrent Treatment:
    Allowed:
    • Radiation therapy for mucocutaneous Kaposi's sarcoma.

    Not previously treated for acute cryptococcal meningitis and not eligible for Pfizer Central Research, protocol #159.

    • Patients must have a baseline cerebrospinal fluid (CSF) culture-positive for Cryptococcus neoformans.

    • Written informed consent must be obtained for each patient, either from the patient himself or from the patient's legal guardian.

    • Each individual patient must be approved by Pfizer Central Research prior to study entry.

    Prior Medication:
    Allowed:
    • Immunosuppressant therapy.

    • Antiviral therapy such as zidovudine.

    • Prophylaxis for Pneumocystis carinii pneumonia.

    • Aerosolized pentamidine.

    Exclusion Criteria

    Co-existing Condition:
    Patients with the following are excluded:
    • Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.

    • History of allergy to or intolerance of imidazoles or azoles.

    • Moderate or severe liver disease.

    Concurrent Treatment:
    Excluded:
    • Lymphocyte replacement.
    Patients with the following are excluded:
    • Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.

    • History of allergy to or intolerance of imidazoles or azoles.

    • Moderate or severe liver disease.

    • Satisfactory response to amphotericin B and have received a total amphotericin B dose of 15 mg/kg or more since CSF culture documentation of the current episode of acute cryptococcal meningitis.

    • Life expectancy of < 2 weeks.

    Prior Medication:
    Excluded:
    • Coumadin-type anticoagulants.

    • Oral hypoglycemics.

    • Barbiturates.

    • Phenytoin.

    • Immunostimulants.

    • Investigational drugs or approved (licensed) drugs for investigational indications.

    Prior Treatment:
    Excluded:
    • Lymphocyte replacement.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Univ of Alabama at Birmingham Birmingham Alabama United States 35294
    2 George Washington Univ Med Ctr Washington District of Columbia United States 20037
    3 Univ of South Florida Tampa Florida United States 33612
    4 Emory Univ School of Medicine Atlanta Georgia United States 30303
    5 Med College of Georgia Augusta Georgia United States 30912
    6 Univ Hosp Boston Massachusetts United States 02118
    7 Ann Arbor Veterans Administration Med Ctr Ann Arbor Michigan United States 48105
    8 Washington Univ School of Medicine St. Louis Missouri United States 63108
    9 Bronx Veterans Administration / Mount Sinai Hosp Bronx New York United States 10468
    10 Saint Luke's - Roosevelt Hosp Ctr New York New York United States 10025
    11 Cincinnati Veterans Adm Med Ctr / Univ Hosp Cincinnati Ohio United States 452670405
    12 United States Air Force Med Ctr Lackland Air Force Base Texas United States 782365300
    13 Southwest Texas Methodist Hosp San Antonio Texas United States 78229
    14 Univ TX San Antonio Health Science Ctr San Antonio Texas United States 78284

    Sponsors and Collaborators

    • Pfizer

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00002306
    Other Study ID Numbers:
    • 012I
    • 056-161
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Jun 24, 2005
    Last Verified:
    Feb 1, 1990

    Study Results

    No Results Posted as of Jun 24, 2005